Limited functionality available
Insights from funding data and investment expert interviews reveal that health care innovators have begun to fill the gap between current and future needs. It's time for health care incumbents to strategize accordingly.
Health care incumbents—providers, payers, life sciences organizations, and transactional players—are working to bend the cost curve and improve care quality. Many leaders say they see consumers and the adoption of advanced technologies as part of future strategies, but they also tell us there are many challenges and barriers to integrating them. The gap between what health care incumbents offer today and what will likely be table stakes in the future of health has created an opening for health tech innovators—nimble, consumer-focused, tech-centric companies. These companies are offering solutions that could help incumbents survive in the new world—whether they become partners or disrupt them (see sidebar, “Health tech defined”).
The Deloitte Center for Health Solutions found that venture capitalists, certain private equity investors, and corporate venture funds are investing in products, services, and solutions that will enable the future of health. We interviewed 15 health tech investors and analyzed data for 2011 through 2019 from Rock Health’s Digital Health Funding Database. We found:
Explore the Life sciences collection
Learn about Deloitte's services
Go straight to smart. Get the Deloitte Insights app
Health care incumbents should pay attention to these trends as they plan their strategies for the future. Health tech innovators are developing capabilities, products, and services that will likely be critical to the future of health. And as health tech investors and innovators continue to develop differentiated products and solutions for this market, they should consider where the industry is headed in the future. New archetypes may require new companies and solutions to address aspects of health that go beyond traditional services and capabilities.
Health tech, as the name suggests, is the convergence of health care and technology. Our analysis of funding for health tech innovators is based on data from Rock Health. Rock Health tracks innovators where technology itself is a product or service. It excludes companies that may have technology as an enabler, but are focused on nontech services and solutions. For instance, the data set doesn’t include organizations like Oscar Health, Clover Health, or One Medical.
Funding for health tech innovators exceeded US$7.4 billion in 2019 and funding data shows that investors continue to be bullish about investing in the health tech field.1
Venture funding to innovative companies is often considered an important barometer of their value propositions and long-term success. Moreover, it can indicate future market performance and emerging trends. To that end, we analyzed where investors—traditional VC firms and CVCs—are placing their bets in the future of health. We interviewed executives from 15 health care and nonhealth care VCs and CVCs and analyzed funding for health tech innovators between 2011 and 2019 using Rock Health’s Digital Health Funding Database. (For details, see sidebar, “Methodology.”)
Quantitative analysis: We conducted data analysis of venture capital deals in the health tech space using data from Rock Health. We classified the innovators based on:
Executive interviews: We interviewed 15 executives from the investor community, both VC and CVC, to understand their views on health tech investments and the future. Interviews focused on top and emerging areas of investment, challenges facing health tech innovators, and core capabilities needed by innvators to succeed in health care, among other topics.
Venture investors are often accused of chasing shiny new objects, such as innovators with elaborate technologies or untested products, in pursuit of unearthing the next unicorn—without proper due diligence on the sustainability and impact of their value proposition. In health care though, that may not be the case. Investors we interviewed agreed about the fundamental issues facing the industry. They are backing innovators that align their value propositions to the present and future of health, with technology being the bedrock. Investors repeatedly emphasized that these organizations should:
By 2040, health care as we know it today will no longer exist, as “health care” will have shifted to “health.” Through this transformation, we predict that new archetypes, or business priorities, for stakeholders in health care, technology, and more will emerge. The archetypes will likely fall into three distinct, but interconnected, categories:
We took Rock Health data on digital health funding from 2011 through 2019 and mapped each company’s value proposition to these three categories. In doing so, we found that historically, data and platform innovators have received the highest funding. But funding in this area plateaued in 2018, while funding for well-being and care delivery innovators accelerated. After steady growth from 2011 to 2017, funding for well-being and care delivery innovators doubled in 2018 to more than US$4 billion from a year earlier. While funding dipped in this category in 2019, it remains well above funding for data and platform innovators (figure 1). (See sidebar, “2018: An all-star year for health tech.”)
HeartFlow is a well-being and care delivery innovator and is transforming how clinicians treat and diagnose cardiovascular disease. It provides a noninvasive test that peeks into a patient’s coronary arteries to diagnose blockages. Traditionally, such a diagnosis involves an invasive, painful, and slightly risky procedure. Using deep-learning algorithms, the test receives comparable measurements from a CT scan. For a US$1,450 test, HeartFlow claims it prevents US$4,000 in further costs. In the United States, commercial plans and Medicare pay for this test. The United Kingdom’s National Health Service (NHS) has rolled out the test in more than 40 hospitals since 2017.2 HeartFlow raised US$65 million in its latest funding round.3
Health Catalyst is a data and platform innovator founded in 2008. Its proprietary “Data Operating System” (DOS) is a data warehousing product that helps health care organizations combine data from different data systems into a single cloud-based platform for decision-making. It also provides add-on AI-driven analytics solutions and services. With data and insights from Health Catalyst, more than 120 health care organizations have improved quality of care, cut turnaround times, and reduced costs.4 For instance, a regional health system achieved a 36.4 percent reduction in sepsis mortality rate using Health Catalyst’s data platform and analytics applications. Similarly, another regional health system saved US$17.4 million by reducing unnecessary blood transfusions through predictive modeling to risk-adjust blood utilization specific to patient case-mix.5 Health Catalyst raised US$100 million in its last round of funding in early 2019.6
According to Rock Health, 2018 was a record-breaking year for health tech innovators. That year, 380 organizations received funding totaling US$8.2 billion, with an average deal size of US$21.6 million. Much of the difference was that the innovators that eventually conducted initial public offerings (IPOs) in 2019—Livongo and Peloton—raised a combined US$655 million in 2018. As Rock Health puts it, “Moderation, rather than contraction, best describes the trend going into 2020.”7
Several investors we interviewed said that technology will be a critical enabler in the future of health. However, success for health tech innovators may hinge on their ability to pair a differentiated technology with the right value proposition to create a sustainable business model.
“Technology is an enabler of existing workflows and process that haven’t been able to scale historically.”
—Health tech investment expert
We found that as of 2019, only about half (52 percent) of these organizations are using differentiated technology—emerging technologies that could transform business models—as a foundation for their products or services. Of the innovators with a differentiated technology, those leveraging AI, ML, and IoT received the most funding in 2019 (figure 2). Experts said that proof points from pilots, greater clinical validation, more responsive regulatory frameworks, and fundamental technology changes—such as the exponential increase in computing capabilities coupled with a reduction in costs—are driving greater investment in AI and ML technologies. A few experts said that the exponential increase in funding for this area could be a short-lived hype cycle, however. There is also growing concern from investors around the “black box” problem—that it is too difficult to understand how algorithms make their decisions.
Butterfly Network aims to democratize ultrasound technology. Ultrasound technology is an essential part of diagnosis and well-being monitoring today. But standard ultrasound machines are bulky, expensive, and at times, cumbersome to use. Butterfly Network’s flagship product Butterfly IQ is a handheld device the size of a smartphone and uses a single semiconductor chip instead of typical piezoelectric crystals. Starting at under US$2,000, it is 80 percent less expensive than previous attempts to make ultrasound machines portable.8 By making ultrasound imaging easy to use and more accessible, the company is hoping to give doctors a real-time understanding of the body without some of the harmful risks and delays associated with radiation-based imaging technologies. The company is already making inroads beyond the US market—in Europe, Asia, and even Africa—to provide accessible and affordable imaging to “two-thirds of the world’s population who get no imaging avenues at all.”9
Ginger.io, founded in 2011, is helping Americans cope with mental and behavioral health issues through technology. About 50 percent of all Americans are diagnosed with a mental illness or disorder, such as depression, at some point in their lifetime.10 Ginger.io’s app provides users access to emotional care and counseling by connecting with health coaches through video chats and chat messages, either in real time or through virtual appointments. Ginger.io’s AI algorithms analyze data from the user’s smart phone to relate their behavior with their health. Based on the data and insights, the app creates a personalized care plan with an emphasis on the required behavioral changes for a healthier life. The company claims that 72 percent of its members have shown clinically significant improvements in symptoms of depression within 12 weeks.11
The value and money flow in health care is different than most other industries. In retail, consumers use their money to directly purchase goods from the retailer. Even with banks, which are as highly regulated as health care, the money flows between the consumer and the bank. In health care, this is very different—thus creating one of the biggest challenges for innovators in this industry. As one expert put it, “these organizations have to figure out how to fight on both fronts”—the consumers and the health care system—because money doesn’t flow directly from the patient to the doctor, even if the value does.
Rock Health analysis confirms the challenges to succeed in this industry: Only 9 percent of innovators founded between 2010 and 2019 have either been acquired or conducted an initial public offering (IPO) (figure 3). Data and platform innovators had the most exits during those years.
2019 ended a three-year drought of health tech IPOs. A record-breaking five health tech IPOs took place in 2019: Livongo, Health Catalyst, Change Healthcare, Phreesia, and Peloton.12 Combined, they raised more than US$2.7 billion in cash, at a combined valuation of US$18 billion.13 The valuation is a testament to their winning value propositions—data and platform (Change Healthcare, Health Catalyst), well-being and care delivery (Livongo, Peloton), and care enablement (Phreesia). However, reaching this valuation took time; all but one was founded before 2010.
According to Deloitte’s 2019 Health Care CEO Perspectives Study, many leading health care organizations are developing investment funds to prepare for the ubiquitous change ahead, as technology becomes even more integrated into life, work, and culture. However, our Rock Health analysis reveals that while VCs are increasingly investing in health tech, participation of CVCs has remained stable since 2015 (figure 4).
Participation by corporate investors varies by area of focus. For example, investor arms of health care companies have focused on care enablement, as well as well-being and care delivery. Life sciences and technology companies have increasingly participated in data and platform deals. Technology CVCs—nonhealth care entrants seeking to disrupt the health care industry—have invested in data and platform, and well-being and care delivery innovators evenly. (See sidebar, “New entrants: Disrupting health care, not health care organizations.”)
Tech giants such as Google, Amazon, and Apple Inc.14 have been trying to get into the health care industry for the last 10–15 years. Some have had early wins, but many have learned it is difficult to disrupt from the inside out due to the inherently complicated nature of the industry (operations, regulations, etc.).
Deloitte’s 2019 Survey of Health Care Strategy Leaders found that 57 percent view competition from traditional and new entrants as their top source of concern. Indeed, disrupters often have the value proposition to tackle waste in health care—they are nimble, efficient, consumer-centric, solution-focused. But interviews with experts indicated that many believe incumbents should be a part of the change for disrupters to be successful. New entrants should work with large incumbents through partnerships and collaborations to blend their value proposition with the right health care expertise and disrupt health care.
According to Deloitte’s 2019 Health Care CEO Perspectives Study, however, many health care CEOs have mixed views. While many admit that the industry is ripe for disruption, and that these companies have the capabilities and dollars to do just that, others believe new entrants are not a threat because they will never deliver complex hospital care.
BlueCross BlueShield Venture Partners (BCBSVP), the corporate venture arm of the BlueCross BlueShield Association (BCBSA), invests in emerging companies that align with the BlueCross BlueShield (BCBS) strategy. Thirty-three BCBS entities have pledged more than US$575 million across three funds to invest in companies focused primarily on health tech.15 BCBSVP has 33 active venture partners such as:
BCBSVP’s approach is focused on long-term strategic partnerships to drive revenue and distribution, while simultaneously promoting innovation across the industry.
Merck Global Innovation Fund (GHI) is the corporate venture arm of Merck that invests globally in companies with proven technology or business models. Its aim is to increase revenue and enhance value creation. Merck GHI has focused its investments on health tech–centered companies and platforms. It has more than 40 digital health investments and US$500 million in evergreen funds.17 Merck GHI’s investments have concentrated on four major areas: therapy planning, care management, e-clinical trials, and health analytics and AI. Merck GHI’s active health tech investments include:
Merck GHI’s strategy is concentrated on investments that have current revenue, are almost profitable, and that pursue growth capital.
Health tech innovators face a crowded market that is getting more challenging every year. While investment in this space continues to hold steady (despite a small dip between 2018 and 2019), health tech innovator should consider the three following capabilities as they take their products and services to market:
“They have to recognize that as people go through their day, their number one issue isn’t their health. No one got up this morning and said, ‘The number one thing I’m worried about is preventing diabetes.’ They’re focused on how busy they are; how stressed they are”
—Health tech investment expert
Innovators should also consider the following key questions when building their products and solutions:
Finally, health tech innovators may consider the various benefits of working with CVCs early in the process:
However, according to the experts we interviewed, CVCs can often be very rigid and too narrow in their focus. They might not allow the innovator to be nimble. Hence, such organizations may avoid early-stage funding from a CVC, when they might have to pivot the business on market needs.
“Sometimes they’ll have the best tech, but they’re not really solving a problem that needs solving.”
—Health tech investment expert
Life sciences and health care companies can also work closely with organizations that are working on products and solutions that align with their strategic priorities.
Health care incumbents should pay attention to these trends as they plan their strategies for the future. Health tech innovators are developing capabilities, products, and services that will likely be needed in the future of health. And as health tech investors and innovators continue to develop differentiated products and solutions for this market, they should consider where the industry is headed in the future. New archetypes may require new companies and solutions that address aspects of health that go beyond traditional services.